



Panel:

Early-Age Onset Colorectal
Cancer: Scientific Updates and
Member Work to Increase
Action and Awareness

2:20 PM - 3:30 PM

Panel: Early-Age Onset Colorectal Cancer: Scientific Updates and Member Work to Increase Action and Awareness



Moderator
Peter Liang, MD, MPH
NYU Langone Health



Yin Cao, ScD, MPHWashington University School of Medicine in St Louis



Lynn M. Durham, EdDGeorgia Center for Oncology
Research and Education



Cynthia Yoshida, MDUniversity of Virginia Health
System



Andrea (Andi) Dwyer, MPH University of Colorado Cancer Center; Colorado School of Public Health

Early-onset Colorectal Cancer (EOCRC) Scientific Update

Yin Cao, ScD, MPH

Associate Professor of Surgery and Medicine Co-Director, Biobank and Big Data Core, Digestive Disease Research Core Center Co-Team Lead, PROSPECT of Cancer Grand Challenges

ACS NCCRT Annual Meeting, November 19th, 2025





Disclosures




- Yin Cao, ScD, MPH
- Consulting fees from Need and Bayer.

Outline



- EOCRC global incidence and molecular characteristics
- Risk factors
- Emerging mechanisms and frameworks
- Early detection and diagnosis

EOCRC is increasing in 27 countries (2008–2017*)




^{*}Exceptions are Costa Rica and Spain (2005–16) and Japan (2006–15).


EOCRC clinicopathological features, US


Majority are left-sided

Advanced stages, poorly differentiated




Cercek et al., JNCI, 2021





Majority are sporadic



Sinicrope, NEJM, 2022

EOCRC genomic landscape



- 4983 EOCRC vs. 12150 LOCRC (8 countries)
- Target panel + WES

Country	EOCRC (%)
USA	82%
China	13%
Other 6 countries	5%


EOCRC:

- Higher mutation frequency in 137 genes including TP53, TCF7L2, CTNNB1
- Lower mutation frequency in 6 genes: BRAF, RNF43, SOX9, AXIN2, HNF1A, ELF3

EOCRC vs LOCRC				
Hypermutated	Non-hypermutated			
\uparrow APC, \uparrow KRAS, \uparrow CTNNB1	↑ <i>TP53</i>			
J BRAF, J RNF43	\downarrow BRAF, \downarrow KRAS			

EOCRC mutational signatures

- 132 EOCRC vs. 849 LOCRC (11 countries)
- WGS T/N
- Colibactin signatures (SBS88, ID18) more common in EOCRC





	Colorectal cancers	
Total	981	
Number of Countries	11	
Europe		
Russia	147	
Poland	94	
Serbia	83	
Czech Republic	56	
Asia		
Iran	111	
Thailand	104	
Japan	28	
South America		
Brazil	159	
Argentina	53	
Colombia	36	
North America		
Canada	110	



EOCRC mutational signatures

- 132 EOCRC vs. 849 LOCRC (11 countries)
- WGS T/N
- Colibactin signatures (SBS88, ID18) more common in EOCRC





Outline



- EOCRC global incidence and molecular characteristics
- Risk factors
- Emerging mechanisms and frameworks
- Early detection and diagnosis

Challenges and opportunities in EOCRC risk factor discovery





Cancer is rare

Lack of longitudinal data across the lifespan

Lack of repeated biospecimen collection

Reproducibility

New data collections

Efficient study design

Data fusion (cohorts, EHR-biobanks, clinical, mobile, geocoded, multi-omics)


Casual inference (e.g., G methods, life course mendelian randomization)

Systems and network modeling

Kuh & Ben-Shlomo, Oxford 2004
Hanson et al, J Clin Transl Sci 2020
Wright & Hanson, Trends in Cancer 2022
Wagner et al, Lancet Public Health 2024

EOCRC risk factors that are common and emerging in recent generations (Cao lab, 2017+)





(timing)
Gastroenterology, 2023

Hofseth et al., Nat Rev Gastro, 2020 Sinicrope, NEJM, 2022 Zaki et al., Nat Rev Gastro, 2023 Du et al., Nat Rev Endocrinol, 2025

Recent evidence on antibiotic use



- Nested case-control study, Kaiser Permanente Northern California
- 1359 EOCRC vs. 4711 controls


No associations for antibiotic type (any, by spectrum, bacterial target, class) and duration of use

	Time Interval for Antibiotic Use Prior to Index Date				
Antibiotic Type	No Previous Use	2-4 y vs No Prior Use	5-7 y vs No Prior Use	≥8 y vs No Prior Use	
Any					
Cases	99	194	191	254	
Controls	306	643	614	868	
OR (95% CI) ^a	1.00 (Ref)	1.00 (0.78-1.30)	1.06 (0.83-1.37)	0.88 (0.64-1.21)	
OR (95% CI) ^b	1.00 (Ref)	1.01 (0.78–1.30)	1.07 (0.83–1.39)	0.88 (0.64–1.21)	

Kane et al., Clin Gastroenterol Hepatol, 2025

CANCER GRAND CHALLENGES TEAM PROSPECT





PROSPECT (2024-2029, 25 million direct cost)

Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

https://www.cancergrandchallenges.org/prospect

Team leads:

Yin Cao

Washington University in St. Louis

Andrew Chan

Massachusetts General Hospital















TEAM PROSPECT



Yin Cao, ScD, MPH (co-TL)

Cancer epidemiology

WashU

Gary Patti, PhD
Exposomics/Metabolism


WashU





Andrew Chan, MD, MPH (co-TL)
Gastroenterologist; Cancer prevention

Mass General Hospital



Tim Spector, MD
Clinician; Genetic epidemiology; precision nutrition
King's College London

Nicola Segata, PhD
Computational biology
U Trento





+~30 collaborators
(32% early stage)
+~30 future leaders
+~15 cohorts/biobanks
7 countries



Bhawna Sirohi, MBBS, FRCP

Medical oncologist; Global oncology

BALCO Medical Centre

Ömer Yilmaz, MD, PhD
Pathologist; Stem cell biology
MIT





Curtis Huttenhower, PhD



Yasmine Belkaid, PhD Immunology Institut Pasteur

PIONEERING PATIENT ENGAGEMENT IN PREVENTION RESEARCH





"We found the meaning of our work"

PAs actively engage in all levels of science

"We learned how to communicate science and uncertainty behind it"

 PAs developed 5 big picture questions to help our future leaders communicate science

"They are our bridge to the public"

- Instagram: 993K views with extensive engagement
- Media engagement: Times, BBC, Telegraph, Sun, Daily Express, ITV's Lorraine


Outline





- EOCRC global incidence and molecular characteristics
- Risk factors
- Emerging mechanisms and frameworks
- Early detection and diagnosis


EOCRC: an emerging disease of metabolic dysregulation












Mapping exposome throughout life course (Longitudinal)









Ann Zauber




Lansdorp-Vogelaar



Emerging risk factor/mechanisms: circadian dysregulation






Circadian regulation coordinates cell cycle control, DNA repair, immunity, and metabolism in both homeostasis and cancer; yet except shift work, human evidence is limited.

Emerging framework: tumor age

- Tumor age defines time from first neoplastic cell to diagnosis; crucial to understand EOCRC biology.
- EOCRC may evolve faster than standard-onset CRC proposed as "fast-track" tumorigenesis.
- Lowering screening age alone is inadequate for early detection.





Outline



- EOCRC global incidence and molecular characteristics
- Risk factors
- Emerging mechanisms and frameworks
- Early detection and diagnosis

Proposed diagnostic pathways to improve EOCRC early diagnosis



Cassandra Fritz



Manju George



John Carethers

PATIENT FACTORS Patient notices symptoms Abdominal pain Hematochezia

3 Actionable steps for patients

IDA

Diarrhea

- 1. Awareness Know the signs
- 2. Act Do not assume it's not cancer
- 3. **Appointment** Book a visit with a primary care provider within 1 to 2 months if symptoms do not resolve

PROVIDER FACTORS

Symptoms reported to provider



providers

- Increase symptom awareness among providers
- Address family history for highrisk screening
- Assess for laboratory signs (CBC and iron panel)

Actionable (CAN-do) steps for

1. **Consider** CRC despite age

history in the EHR

3. *Navigate* competing


priorities (schedule


follow-up in 4 weeks)

2. Assess and document family

DIAGNOSTIC PATHWAYS

EARLIER DIAGNOSIS of early-onset CRC or reassurance







PATHWAY 2 - TRIAGE



could be considered triage with only positive FIT results going to endoscopy



PATHWAY 3 – ACTIONABLE REASSURANCE

For patients with acute symptoms and low suspicion for early-onset CRC, patients and providers should schedule a follow-up appointment or virtual check-in 4 to 8 weeks after initial presentation. If symptoms are still present, the provider should reconsider pathway 1 or 2. If symptoms have resolved, reassurance and education should be provided.



Abdominal pain, diarrhea, or IDA for symptomatic




Conclusions



- We have made important strides in defining EOCRC molecular features, clarifying risk factors, and identifying gaps in early detection.
- Yet much work remains to truly advance prevention.
- We need all to drive this revolution!
 - Epidemiologists, biologists, geneticists, data scientists, environmental scientists, chemists, toxicologists, behavioral and implementation scientists, economists, modeling...
 - Policy makers, health providers, teachers, parents, patients, general public...
 - Funding agencies and philanthropic support...
 - Next generation of interdisciplinary scientists!!

Acknowledgement

Cao Lab @WashU



















Geisinger































Acknowledgement



WashU

Graham Colditz

Timothy Eberlein

John Olson

Ramaswamy Govindan

Nicholas Davidson

Matthew Mutch

Philip Payne

Philip Tarr

Li Ding

Malachi Griffith

Linda Peterson

Mark Huffman

Kelly Bolton

Meng Wu

*Young-Onset Colorectal

Cancer Program

*Center for the Environment

*Air Quality and Health Initiative

Harvard/MGH/BWH

Edward Giovannucci

Andrew Chan

Walter Willett

Heather Eliassen

Shuji Ogino

Long Nguyen

*CRC research group

UCSD

John Carethers

American Cancer Society

Ahmedin Jemal

MSKCC

Ann Zauber

VUMC

Wei Zheng

MDACC

Ernest Hawk

Fred Hutch Cancer Center

Ulrike Peters

*GECCO Consortium

William Hazelton

UC Irvine

Selma Masri

Institut Pasteur

Yasmine Belkaid

University College London

Charles Swanton

Karolinska Institutet

Jonas Ludvigsson

Erasmus Medical Cancer

Iris Lansdorp-Vogelaar

Imperial College London

Marc Gunter

Team PROSPECT

All co-ls, collaborators, patient advocates, SAB, future leaders

All colleagues of CGC





We look forward to collaborating with you!

yin.cao@wustl.edu



Thank You



Strengthening Georgia's Cancer Fight

Launch + Tactical

Disclosures

- Georgia General Assembly
- Georgia Society of Clinical Oncology
- Amgen

THE CHALLENGE:



Georgia CORE replaces dozens of bar seats with weird looking stools to remind people to check their stool for weird symptoms of colorectal cancer.

We've all sat on a stool where one leg is a lil' off. And a stool that's a lil' off is a sign of colorectal cancer. So, let's replace stools at bars around GA with discolored, wobbly, weirdly shaped stools that have a plaques warning of colorectal cancer signs.



SO WE MADE DOZENS OF WEIRD LOOKING STOOLS...






















October 20



Post

 \Box









TAKE THE PUIZ

Check out this quiz to see your level of risk for colon cancer.

TAKE THE QUIZ

SIGNS AND SYMPTOMS³

- · Stomach pain
- · Unexplained weight loss
- · Changes in bowel habits
- · Blood in stool
- · Funky or skinny poop
- Diarrhea
- Anemia
- Fatigue

Genetics can also play a role. Consider your family history if you have a relative diagnosed with colon cancer.

A 3-MONTH LONG MASS AWARENESS CAMPAIGN

OVER 50 BILLBOARDS ACROSS ATL & HIGH INCIDENCE MARKETS LIKE APPLING, EMANUEL, LEE, TERRELL, CARROLL, WARE, SUMTER, STEPHENS, BURKE












TARGETED META & INSTAGRAM ADS









OUR STOOLS HAVE BEEN MAKING THEIR WAY AROUND THE CREATIVE AND CANCER COMMUNITY



Launch Event – Park Bar



Atlanta Against Cancer x ABV Gallery



CCA Walk to End Colon Cancer

UPCOMING

Wellstar Content

Grady Content & Partnership w/ Community and Creative influencer, Cam Kirk

Northside Hospital Event



Like · 2 1 Reply

Like · 💍 1 Reply · 2 replies

Like · CO 2 Reply

Like · @ 1 Reply

OVER 57K VISITORS TO WEIRDLOOKINGSTOOLS.COM

12,624,926 IMPRESSIONS (PAID MEDIA)

OVER 365 MILLION EARNED IMPRESSIONS!

AJC (online)

AJC (print)

The Telegraph (Macon)

Woman's World

Yahoo!News

Black Press USA

The Atlanta 100

The Grio

Yahoo!News

AOL

WANF - TV (Atlanta, GA)

WRDW (pick-up)

WALB News (pick-up)

MSN (pick-up)

Cancer Health

WAGT (NBC) - Augusta, GA News 26 This Morning

WALB (NBC) - Albany, GA WALB News Atlanta News First

(WANF-CBS) - Atlanta, GA ANF News Live

Peachtree TV - Atlanta, GA - ANF News Live

WHNS (FOX) – Greenville, SC (6PM News)

WCTV (CBS) – Tallahassee, FL (5:30PM News)

WRDW (CBS) – Augusta, GA (News 12 Live at 5)

Peachtree TV - Atlanta, GA ANF AM Live

Atlanta News First (WANF-CBS) - Atlanta, GA ANF AM Live

WHNS (FOX) - Greenville, SC - Morning News

WRDW (CBS) - Augusta, GA - News 12 This Morning

WAGT (NBC) - Augusta, GA News 26 This Morning

Ad Age

PharmaLive

Little Black Book

Media Marketing

Med Ad News


Roastbrief US

Muse by Clios

Indie Agency

The Atlanta Journal-Constitution









f X &

WWIND

Have a seat and let's talk about something we usually don't talk about. This fall across the state, stools are taking center stage to spark conversation about colon cancer.

'Weird Looking Stools' campaign turns heads to start life-saving conversations about colon cancer



PharmaLice.com

MARKETING & ADVERTISING R&D THERAPEUTICS RESOURCES MANNY AWARDS

Log In | Subscribe

CHEMISTRY AND GEORGIA CORE TEAM UP ON 'WEIRD LOOKING STOOLS' CAMPAIGN FOR **COLON CANCER**





Artful stools spark conversation on rising colon cancer rates



Black A NEWS CREATIVE LIBRARY IMMORTAL AWARDS MEMBER COMPANIES

Georgia CORE Sparks Life-Saving Colon Cancer Conversations with 'Weird Looking Stools'

The bold campaign, created with Chemistry, spotlights colon cancer awareness with one-of-a-kind stools created by artist Julian Scalia





HEALTH AND WELLNESS

The Story Behind 'Weird Looking Stools' That Fight Colon Cancer

Inside one of the year's most audacious and artful health campaigns

by Dan Lemaux



Cancer Health

Don't miss out on our weekly cancer treatment

and news updates

Cancer Health



"Weird Looking Stools" in Bars Spark Talks **About Colon Cancer**

AdAge

Creativity Top 5

Biggest advertisers ranked

Agency Review Tracker

Chemistry's 'Weird Looking Stools' bring colon cancer awareness to the bar





Thank You

Medical School Curricula

Early-Age Onset Colorectal Cancer: Scientific Updates and Member Work to Increase Action and Awareness

Cindy Yoshida MD, AGAF University of Virginia Health System

Disclosure

I have no actual or potential conflict of interest in relation to this presentation

Introducing Early-Age Onset CRC into the UVA Medical School Curriculum

Undergraduate 4 years

Medical Student 4 years Medical Resident 3 years

GI Fellow 3 years






- WHO? First year medical students
- WHEN? Pre-clerkship 'classroom learning'
- WHY? Captive/engaged audience, ~100 Gen Z'ers

Why Engage Medical Students in the Fight Against Early-Age Onset CRC?

- 1. Rising incidence in younger adults Awareness/symptom recognition are key to early detection
- 2. Early recognition saves lives Educating future clinicians to recognize red-flag signs can reduce diagnostic delays and improve survival outcomes
- 3. Shift public and professional perception Help clinicians consider CRC in younger symptomatic patients
- 4. Cultivate advocacy and prevention mindset Medical students are the next generation of healthcare providers who can champion timely screening, patient education, and family history awareness
- 5. Enhance interest in research and innovation

Early-Age Onset Colorectal Cancer (EAO-CRC) Increasing in the U.S. and Globally (~1-2% per year)







EAO-CRC Symptoms and Key Facts

Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer

Cassandra D. L. Fritz, MD, MPHS, 1.‡ Ebunoluwa E. Otegbeye , MD, MPHS, 2.‡ Xiaoyu Zong , MPH, 3 Joshua Demb, PhD, MPH, 4.5 Katelin B. Nickel , MPH, 6 Margaret A. Olsen, PhD, MPH, 3.6 Matthew Mutch, MD, 7 Nicholas O. Davidson, MD, DSc, 1 Samir Gupta, MD, MSCS, 4.5,8,9.§ Yin Cao , ScD, MPH, 1.3,10,*,§







Rectal bleeding



Iron deficiency anemia



Change in bowel habits

Age < 50 Red Flag Signs (3 mos – 2 y before index CRC)

# signs/symptoms	Risk of EAO-CRC (OR)	
1	1.9 x	
2	3.6 x	
3	6.5 x	

- Deadliest cancer in young men and 2nd deadliest in young women
- Predominantly left colon and rectal distribution;
 higher proportion of mucinous/signet ring
 histologic subtype
- Often diagnosed at more advanced stages
- Young pts experience **delays in diagnosis** due a personal or provider failure to associate red-flag symptoms with an ↑ risk of CRC
- Young patients who present with red flag symptoms should be referred for further evaluation (e.g., colonoscopy or referral to GI).


Early-Age Onset CRC: Birth Cohort Effect

(1928 - 1945)

(1901 - 1927)

(1946 - 1964)


(1965 - 1980)



(1981 - 1996)

(1997-2012)

EAO-CRC Potential Causes/Mechanisms



Can the ACS NCCRT Scale This Idea For All Medical Schools?

Growing its impact from a successful pilot to a widespread educational product



that can effect deep and meaningful change

for a greater number of students and schools

ACS NCCRT EAO-CRC Educational Toolkit Slide Set With Notes/References



EAO-CRC Symptoms and Key Facts

Red-flag signs and symptoms for earlier diagnosis of early-onset colorectal cancer

Cassandra D. L. Fritz, MD, MPHS, ^{5,1} Ebunoluwa E. Otegbeye (), MD, MPHS, ^{5,1} Xiaoyu Zong (), MPH, ¹Joshua Demb, PhD, MPH, ^{6,5} Katelin B. Nickel (), MPH, ¹Margaret A. Oisen, PhD, MPH, ^{6,5} Marthew Mutch, MD, ¹Nicholas O. Davidson, MD, DSC, ¹Samir Cupta, MD, MSCS, ^{5,5,5,6} (), Tin Cao (), Sc, Ophill^{1,1,2,5,6} ()












Age < 50 Red Flag Signs (3 mos – 2 y before index CRC)

# signs/symptoms	Risk of EAO-CRC (or)	
1	1.9 x	
2	3.6 x	
3	6.5 x	

- Deadliest cancer in young men and 2nd deadliest in young women
- Predominantly left colon and rectal distribution; higher proportion of mucinous/signet ring histologic subtype
- Often diagnosed at more advanced stages
- Young pts experience delays in diagnosis due a personal or provider failure to associate red-flag symptoms with an † risk of CRC
- Young patients who present with red flag symptoms should be referred for further evaluation (e.g., colonoscopy or referral to GI).

Fritz CDL, et al. JNCl 2023; 115(8):909-916, https://doi.org/10.1093/jncj/djad068 https://colorectalcancer.org/resources-support/community-support/young-onset-support/young-onset-cro-fact

Early-onset colorectal cancer (EAO-CRC) has seen an alarming rise worldwide over the past two decades. The reason for this global trend is poorly understood. EAO-CRC appears to have its own unique clinical and molecular features: EAO-CRC tends to have a predominantly left colonic and rectal distribution, a higher proportion of mucinous and signet ring histologic subtype, poorer cell differentiation, a higher pathologic grade, and a more advanced stage at presentation. Half of EAO-CRC pts are younger than age 45 years and will not be detected via screening. Therefore, most EAO-CRC pts will continue to be diagnosed after developing symptoms. EAO-CRC pts, are more likely to experience diagnostic delays (compared to older pts), indicating a lack of awareness of red-flag signs and symptoms. Younger patients with CRC are more often diagnosed at



Based on current evidence, we postulate <u>exposomal</u> factors, possibly mediated through changes in the microbiome, play a larger role than germline genetics in driving somatic alterations and CRC risk, and that gene-by-exposome interactions likely modify somatic alterations and cancer development

- Exposomal factors such as diet and lifestyle (eg., alcohol, Western diet), early-life exposures (eg., mode of delivery, antibiotics), metabolic disorders (eg., obesity, diabetes), and gut microbiome and metabolites are believed to initiate and/or promote somatic alterations leading to CRC.
- Germline genetic factors such as high-penetrance pathogenic variants (e.g., mismatch repair genes in Lynch syndrome) and moderate- to low-penetrance variants (e.g., single nucleotide polymorphisms) also drive somatic alterations and carcinogenesis.

ACS NCCRT EAO-CRC Educational Toolkit Learning Objectives

- 1. Understand the epidemiologic trends and distinct clinical, histopathologic, and molecular characteristics of earlyage onset colorectal cancer (EAO-CRC).
- 2. Recognize the common presenting symptoms and red-flag warning signs of EAO-CRC, and explain how delayed recognition contributes to diagnosis at more advanced stages.

ACS NCCRT EAO-CRC Educational Toolkit Questions/Assessment

Application/Clinical Scenario Question

A 30-year-old man presents with new-onset rectal bleeding and a change in bowel habits for the past two months. Based on current evidence regarding early-age onset colorectal cancer, what should be the clinician's next step and why?

- A. Wait until he is 45 years old to initiate colorectal cancer screening
- B. Colonoscopy or referral to gastroenterology
- C. Reassure the patient that his symptoms are likely due to hemorrhoids
- D. Schedule a follow-up visit in 6 months to see if the symptoms persist

Correct Answer: B


Prompt diagnostic evaluation (e.g., colonoscopy) should be performed rather than attributing symptoms to benign causes as these red-flag signs are associated with a significantly increased risk of EAO-CRC and early detection can improve outcomes.

Engaging Young Trainees in Virginia

- UVA Medical School Curriculum
- March EAO-CRC Social Media Campaign
 - UVA GI fellowship, UVA Internal Medicine Residency,
 UVA Health and UVA Cancer Center Instagram posts
- Virginia Colorectal Cancer Roundtable (VCCRT) Trainee Corner
 - Internal Medicine Residents/GI fellows from UVA,
 Virginia Tech, VCU, Inova
 - Presentations at quarterly meetings
 - Statewide March 2026 EAO-CRC Campaign







Education is the most powerful weapon which you can use to change the world

- Nelson Mandela



Thank You

GLOBAL EARLY ONSET COLORECTAL CANCER THINK TANK (GEOCRCTT)

Andrea (Andi) Dwyer, MPH Advisor Fight CRC Medical Advisory Board Member

No Disclosures

The GEOCRCTT team

ADVISORY TEAM



ANDREA (ANDI)

DWYER

Advisor to Fight CRC,

University of Colorado

Cancer Center



DR. ANDREW
(ANDY) CHAN
Professor of Medicine,
Massachusetts General Hospital



DR. JOSÉ PEREA
GARCÍA
Chief Department of Surgery,
Institute of Biomedical Research
of Salamanaca (IBSAL)

SUPPORT TEAM



DR. KIRAN ILAGANDirector of Research Advocacy,
Fight CRC



RYAN SOISSON
Facilitator,
Founder of Soisson's & Associates

Sponsors and Partners











GLOBAL **COLON CANCER ASSOCIATION**





GEOCRCTT RECAP





GEOCRCTT RECAP





An invitation to participate in a 2-year global initiative (beginning with a conference)

GOAL:

Develop and begin to execute a unified global research strategy addressing the rise of early onset colorectal cancer

Objectives

- **1.Research Community:** Develop connections and unity among the global research community working on EOCRC.
- **2.Understand Drivers**: Deepen our understanding of the suspected etiologic drivers of EOCRC based on research in each of the represented regions.
- **3.Launch Initiative**: Launch an initiative and post-conference workgroups to determine a way forward to support this work. Create workgroup charters and identify members.



IN SCOPE:

Etiologic Drivers of EOCRC

- Lifestyle and Environmental Factors
- Biological Factors
- Molecular Pathways
- Life Course & Exposures

OUT OF SCOPE:

- Health System Interventions
- Screening Programs
- Insurance Coverage
- Screening Guidelines



Agenda At a Glance

JUNE 18, 16:30-23:00			
16:30	Welcome		
16:40	Getting to know each other		
16:55	Tonight, tomorrow, and beyond		
17:05	International advocacy groups		
18:05	The patient perspective		
19:00	Dinner		
21:00	Cocktails		

JUNE 19, 8:00-17:00				
9:00	Introduction			
9:20	Connecting as global partners			
9:45	Global perspective: Most recent data			
11:00	Regional perspective: Etiologic drivers from around the globe, Pt 1.			
12:05	Lunch			
12:55	Regional perspective: Etiologic drivers from around the globe, Pt 2.			
13:30	Etiology drivers review			
14:00	Our Workgroups			
14:50	Workgroup breakouts			
16:30	Moving forward			

Themes Explored & the Need to Design and Build Global Perspective:

The rise in early-onset CRC is a global phenomenon, and understanding its causes and solutions requires looking beyond our own borders. *Engaging in international research helps us uncover patterns, risk factors, and disparities that would remain invisible in a single-country study.*

Experts confirmed:

- EOCRC incidence is rising in countries like the U.S., Australia, Canada, Germany, and more — even as overall CRC rates fall.
- Mortality rates for young patients are rising, proving this is a true increase in disease, not just improved detection.
- Patterns do not vary by sex, making hormonal causes unlikely.
- The disease primarily affects the rectum and sigmoid colon, with many patients diagnosed at later stages.

Participants discussed factors requiring urgent study:

- Dramatic shifts in diet and higher processed food consumption.
- Circadian rhythm disruptions from night shifts or poor sleep.
- Emerging evidence of microbiome changes.
- Genetic predispositions and potential novel mutations.
- Regional disparities suggesting unique local drivers.

Post-Event Feedback

We successfully started to...



Strongly disagree Strongly agree

ACROSS WORKGROUP

Scientific Research Themes	Epi Tools	Biobanking	Risk Stratification
 Research topic groups drafted from member input Member poll to identify top priority areas Each group to develop a consensus paper (evidence, gaps, recommendations) Next meeting: confirm assignments, timeline, and support 	 Launch of two subgroups: Global Data Repository Map existing datasets; does not store new data Detail access processes and limitations May link to publications and user feedback Potential scoping review to identify data gaps Common Data Elements Build on existing draft survey modules (Fight CRC collaborators) Identify priority domains and knowledge gaps Promote standardization for cross-study analysis Dynamic resource updated as the field advances 	 Survey circulated to identify existing CRC biobanks and available data Gathering global input to map resources and collaboration opportunities Systematic review registered on PROSPERO to catalogue EOCRC biobanks 	 Member survey launched to shape priorities and collaborations Focus on three domains: Identifying increased risk (symptomatic & asymptomatic) Risk-informed intervention strategies Awareness & education for public and providers Responses will guide next steps and subgroup formation


Upcoming Opportunities to Contribute:

Need Input:

Biobanking

Epi Tool Collections (contact Andi details)

Relaunch of Patient Facing Global Survey





Upcoming Gathering Times Join Us:

AACR Meeting – December 10 to 13 2025 | Montreal, QC, Canada

GI ASCO Meeting January 8 to 10, 2026

ESMO Munich July 1 to 4, 2026

Full Member Reconvening in Summer of 2027 (Date TBD)







Thank You

CONTACT KIRAN ILAGAN: KIRAN@FIGHTCRC.ORG To Join The GEOCRTT







Questions